1,25 Dihydroxyvitamin D 3 and Osteomalacia: Some Unanswered Questions

Haussler M.R. , Baylink D.J. , Hughes M.R. : The assay of 1a, 25 dihydroxyvitamin D₃: physiologic and pathologic modulation of circulating hormone levels. Clin. Endocrinol. 5: 151, 1976.

Eisman J.A. , Hamstra A.J. , Kream B.E. : A sensitive, precise and convenient method for determination of 1,25 dihydoxyvitamin D₃ in human plasma. Arch. Biochem. Biophys. 176: 235, 1976.

Jubiz W. , Hausier M.R. , McCain T.A. : Plasma 1,25 dihydroxyvitamin D₃ levels in patients receiving anticonvulsant drugs. J. Clin. Endocrinol. Metab. 44: 617, 1977.

Tanaka T. , Frank H. , DeLuca H.F. : Biological activity of 1,25 dihydroxyvitamin D₃ in the rat. Endocrinology 92: 69, 1973.

Ellis H.A. , Peart K.M. : Azotaemic renal osteodystrophy: a quantitative study on iliac bone. J. Clin. Pathol. 26: 83, 1973.

Bordier J. , Chot S.T. , Eastwood J.B. : Lack of histological evidence of vitamin D abnormality in the bones of anephric patients. Clin. Sci. 44: 33, 1973.

Kanis J.A. , Adams N.D. , Earnshaw M. : Vitamin D, osteomalacia, and chronic renal failure. In: Vitamin D. Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism. Norman A.W. , Schaefer K. , Coburn J.W. , DeLuca H.F. , Fraser D , Gricoleit H.G. , Herath D.V. (eds). Walter de Gruyter, Berlin - New York, p. 671, 1977.

Dent C.E.A. , Richens A. , Lowe D.J.F. : Osteomalacia with long term anticonvulsant therapy in epilepsy. Br. Med. J. 4: 69, 1970.

Brooks M.H. , Bell N.H. , Love L. : Vitamin D dependent rickets type II; resistance of target organs to 1,25 dihydroxyvitamin D₃. N. Engl. J. Med. 298: 996, 1978.

DeLuca H.F. : Vitamin D metabolism and function. Arch. Intern. Med. 138: 836, 1978.

Eastwood J.B. , DeWardener H.E. , Gray R.W. : Normal plasma 1,25 (OH)₂ vitamin D₃ concentrations in nutritional osteomalacia. Lancet 1: 1377, 1979.

Brickman A.S. , Sherrard D.J. , Jowsey J. : 1,25 Dihydroxycholecalciferol: effect on skeletal lesions and plasma parathyroid hormone in uremic osteodystrophy. Arch Intern. Med. 134: 883, 1974.

Pierides A.M. , Ward M.K. , Alvarez-Ude F. : Long term therapy with 1,25 (OH)₂ D₃ in dialysis bone disease. Proc. Europ. Dial. Transplant. Assoc. 12: 237, 1975.

Coburn J.W. , Brickman A.S. , Sherrard F.R. : Clinical efficacy of 1,25 dihydroxyvitamin D₃ in renal osteodystrophy. In Vitamin D₃. Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism, Norman A.W. , Schaefer K. , Coburn J.W. , DeLuca H.F. , Fraser D. , Grigoleit H.G. , Herath D.V. (eds.). Walter de Gruyter, Berlin-New York, p. 657, 1977.

Bordier P. , Rasmussen H. , Marie P. : Vitamin D metabolites and bone mineralization in man. J. Clin. Endocrinol. Metab. 46: 284, 1978.

Bordier P. , Zingraff J. , Gueris J. : The effect of 1a OH D₃ and 1a, 25 (OH)₂ D₃ on the bone in patient with renal osteodystrophy. Am. J. Med. 64: 101, 1978.

Berl T. , Berns A.S. , Huffer W.E. : 1,25 Dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann. Intern. Med. 88: 774, 1978.

Pierratos A. , Oreopoulos D.G. , Rabinovich S. : The effect of 1,25 (OH)₂ vitamin D₃ on renal osteodystrophy. Royal College of Physicians and Surgeons of Canada, Montreal, p. 87, Jan 1979.

Ahmed K.Y. , Varghese Z. , Wills M.R. : Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Lancet 1: 629, 1978.

Malluche H.H. , Goldstein D.A. , Massry S.G. : Management of renal osteodystrophy with 1,25 (OH)₂ D₃. II. Effects on histopathology of bone: evidence for healing of osteomalacia. Mineral Electrolyte Metab. 2: 48, 1979.

Henderson R.G. , Russell R.G.G. , Ledingham J.G.G. : Effects of 1,25 dihydroxycholecalciferol on calcium absorption muscle weakness, and bone disease in chronic renal failure. Lancet 1: 379, 1974.

Silverberg D.S. , Bettcher K.B. , Dossetor J.B. : Effect of 1,25 dihydroxycholecalciferol in renal osteodystrophy. Can. Med. Assoc. J. 112: 190, 1975.

Russell R.G.G. , Kanis J.A. , Smith R. : Physiological and pharmacological aspects of 24, 25 dihydroxycholecalciferol in man. Adv. Exper. Med. Biol. 103: 487, 1977.

Kanis J.A. , Cundy T. , Bartlett M. : Is 24,25 dihydroxycholecalciferol a calcium regulating hormone in man? Br. Med. J. 1: 1382, 1978.

Walling M.W. , Hartenbower D.L. , Coburn J.W. : Effects of 1a, 25 and 1a, 24R, 25 hydroxylated metabolites of vitamin D₃ on calcium and phosphate absorption by duodenum from intact and nephrectomized rats. Arch. Biochem. Biophys. 182: 251, 1977.

Szymendera J. , Galus K. : Effect of 24,25-dihydroxycholecalciferol on calcium absorption in proximal small intestine in uraemia. Br. Med. J. 2: 1465, 1978.

Fournier A. , Bordier P. , Gueris J. : Comparison of la hydroxyvitamin D₃ and 25 hydroxyvitamin D₃ in the treatment of renal osteodystrophy: greater effect of 25 hydroxyvitamin D₃ in mineralizating bone. In: Vitamin D. Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism, Norman A.W. , Schaefer K. , Coburn J.W. , DeLuca H.F. , Fraser D. , Grigoleit H.G. , Herath D.V. (eds). Walter de Gruyter, Berlin-New York, p. 667, 1977.

Brancaccio D. , Graziani G. , Galmozzi C. : 25-Hydroxyvitamin D deficiency and osteomalacia of chronic renal failure. Lancet 1: 199, 1977.

Ward M.K. , Feest T.G. , Ellis H.A. : Osteomalacic dialysis osteodystrophy: evidence for a water-borne aetiological agent, probably aluminum. Lancet 2: 841, 1978.

Oreopoulos D.G. , Pitel S. , Husdan H. : Contrasting effect of hemodialysis and peritoneal dialysis on the inhibitor of in vivo calcifications by uremic serum. Can. Med. Assoc. J. 110: 43, 1974.